Blavatnik Fund for Innovation at Yale
PitchFest
Dec 3rd, 2021
An Urgent Need to Expand Access to Transplant

Patients wait on average 5 years to get a kidney transplant in the U.S.

During that 5-year wait, ~25,000 donor kidneys will go unused.

5 years of dialysis equals ~$350k in health care cost per patient.
Surgeons are forced to make *life or death decisions* on scant information. The wrong decision can mean *death for their patient and loss of their transplant program* due to strict regulatory oversight.

Advancing American Kidney Health executive order mandates the *# of kidney transplants double by 2030*.

*Transplant Centers Desperately Need a Way to Reduce Their Risk*
Revalia Bio’s Value Proposition for Transplant Centers

Expand your transplant volume without expanding your risk

**Personalized Organ Diagnosis**
AI-guided analytics for **personalized diagnosis of every donor organ** to identify the right repair regimen

**Pre-Transplant Organ Repair**
Tailored therapies delivered prior to transplant to **prevent acute injury and provide durable protection post-transplant**
Our Proprietary Approach to Organ Repair

We diagnosis and repair organs outside the body with organ perfusion.

Program for Ex Situ Research In Declined Human Organs

Unique access to:
- ~150 Declined Human Kidneys/yr
- 1000’s of previously banked samples

Our exclusive access to donor tissue samples and demographic information enables rapid development of AI-driven diagnostics.

REVALIA BIO
Making every organ matter
Our proprietary nanomedicine technology improves the potency of targeted drug delivery by >1000x.
None of these competitors address the fundamental customer need to reduce risk like Revalia Bio

Tissue Engineering

Xenotransplantation
Our Founding Team

Greg Tietjen, PhD
Co-Founder
Assistant Professor
Yale School of Medicine

Expertise:
› Drug delivery
› Ex vivo organ perfusion
› Clinical Translation

Shohei Koide, PhD
Co-Founder
Professor
NYU Langone Health

Expertise:
› Protein Engineering
› Serial Inventor
› Multiple Biologics in IND

Kourosh Saeb-Parsi, MD/PhD
Co-Founder
Professor
University of Cambridge

Expertise:
› Clinical Organ Transplant
› Ex vivo organ perfusion
› Serial Entrepreneur
How we will use $300k from the Blavatnik Fund

- **$150k for perfusion consumables for a first-in-human clinical trial** to assess pre-transplant treatment of organs with a biologic therapy (IDE in preparation)

- **$75k for a prototype diagnostic software platform** built in collaboration with Terawe Inc, a leading cloud-based IT solutions provider

- **$75k for preclinical validation of our lead nanomedicine therapy** in a large animal transplant model and transplant-declined human organs